EAM
LRMR icon

EverPoint Asset Management’s Larimar Therapeutics LRMR Stock Holding History

EverPoint Asset Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-6,250
Closed -$2.97M – 528
2015
Q1 		$2.97M Buy
+6,250
New +$2.97M 0.06% 368

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

EverPoint Asset Management's LRMR Position: Q2 2015 in Review

EverPoint Asset Management sold out of Larimar Therapeutics (LRMR) in Q2 2015, closing a stake of 6,250 shares — an estimated $2.97M sold.

EverPoint Asset Management first reported a position in LRMR in Q1 2015 and held it in 1 quarter. The position peaked at $2.97M in Q1 2015. 89 funds tracked by Wall St. Rank hold LRMR as of Q2 2015.

  • EverPoint Asset Management reported no remaining Larimar Therapeutics position as of Q2 2015 after selling out during the quarter.
  • EverPoint Asset Management sold 6,250 Larimar Therapeutics shares in Q2 2015, an estimated $2.97M.
  • EverPoint Asset Management first reported a position in Larimar Therapeutics in Q1 2015 and held it in 1 quarter.
  • EverPoint Asset Management's Larimar Therapeutics position peaked at $2.97M in Q1 2015.
  • 89 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2015.

Based on EverPoint Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.